Scholarlink

Background <p>Multidrug-resistant tuberculosis (MDR-TB) undermines global TB control, particularly in high-burden African settings, with high HIV co-infection rates. While Tanzania is among the 30 high-burden TB countries, data on resistance patterns at tertiary referral hospitals remain limited. We aimed to determine the prevalence and factors associated with drug-resistant TB among patients at Muhimbili National Hospital (MNH) in Tanzania.</p> Methods <p>We conducted a retrospective cross-sectional study of 170 TB patients managed at MNH between July 2024 and July 2025.Clinical and demographic data were extracted from hospital records. Resistance was determined using GeneXpert MTB/RIF results extracted from patient records. Rifampicin resistance (RR-TB) detected by GeneXpert was used as the operational indicator of drug-resistant tuberculosis (DR-TB) in this study. The primary outcome was DR-TB, operationally defined by rifampicin resistance detected using GeneXpert MTB/RIF. MDR-TB (resistance to at least isoniazid and rifampicin) was recorded separately when documented in patient records; however, routine isoniazid susceptibility testing was not performed for all patients, so MDR-TB prevalence reflects documented clinical diagnoses rather than systematic testing. Bivariate associations were assessed using Chi-square tests. Multivariable binary logistic regression identified factors independently associated with resistance; due to only 24 resistant cases, the model was limited to two predictors.</p> Results <p>Among 170 patients (64.7% male; mean age 44.2 years, SD 15.6), the prevalence of DR-TB was 14.1% (24/170; 95% CI: 9.5–20.1). Of these, 22 (91.7%) had documented MDR-TB diagnoses in their medical records. On multivariable analysis (limited to two predictors due to low event numbers), HIV co-infection (aOR = 4.82, 95% CI: 1.18–19.67, <i>p</i> = 0.030) and known contact with an MDR-TB patient (aOR = 7.34, 95% CI: 2.45–22.01, <i>p</i> &lt; 0.001) remained significantly associated with resistance. Substantial missing data (up to 78.8%) limits generalizability.</p> Conclusion <p>The prevalence of DR-TB was 14.1%, considerably higher than national averages for new cases (0.9%). HIV co-infection and exposure to known MDR-TB cases were independently associated with resistance. However, these findings are exploratory and hypothesis-generating due to substantial missing data, a small number of resistant cases (<i>n</i>=24), and a single-center design. Prospective multicenter studies are needed to confirm these associations. Nonetheless, targeted interventions for HIV-positive patients and exposed contacts remain a priority.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Factors associated with drug-resistant tuberculosis among patients at a tertiary referral hospital in Tanzania

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月6日

查看全文
  • Ahmed Mohamed Mustafa Elshiekh,
  • Nana Karim Aziz,
  • Sima Rugarabamu

摘要

Background

Multidrug-resistant tuberculosis (MDR-TB) undermines global TB control, particularly in high-burden African settings, with high HIV co-infection rates. While Tanzania is among the 30 high-burden TB countries, data on resistance patterns at tertiary referral hospitals remain limited. We aimed to determine the prevalence and factors associated with drug-resistant TB among patients at Muhimbili National Hospital (MNH) in Tanzania.

Methods

We conducted a retrospective cross-sectional study of 170 TB patients managed at MNH between July 2024 and July 2025.Clinical and demographic data were extracted from hospital records. Resistance was determined using GeneXpert MTB/RIF results extracted from patient records. Rifampicin resistance (RR-TB) detected by GeneXpert was used as the operational indicator of drug-resistant tuberculosis (DR-TB) in this study. The primary outcome was DR-TB, operationally defined by rifampicin resistance detected using GeneXpert MTB/RIF. MDR-TB (resistance to at least isoniazid and rifampicin) was recorded separately when documented in patient records; however, routine isoniazid susceptibility testing was not performed for all patients, so MDR-TB prevalence reflects documented clinical diagnoses rather than systematic testing. Bivariate associations were assessed using Chi-square tests. Multivariable binary logistic regression identified factors independently associated with resistance; due to only 24 resistant cases, the model was limited to two predictors.

Results

Among 170 patients (64.7% male; mean age 44.2 years, SD 15.6), the prevalence of DR-TB was 14.1% (24/170; 95% CI: 9.5–20.1). Of these, 22 (91.7%) had documented MDR-TB diagnoses in their medical records. On multivariable analysis (limited to two predictors due to low event numbers), HIV co-infection (aOR = 4.82, 95% CI: 1.18–19.67, p = 0.030) and known contact with an MDR-TB patient (aOR = 7.34, 95% CI: 2.45–22.01, p < 0.001) remained significantly associated with resistance. Substantial missing data (up to 78.8%) limits generalizability.

Conclusion

The prevalence of DR-TB was 14.1%, considerably higher than national averages for new cases (0.9%). HIV co-infection and exposure to known MDR-TB cases were independently associated with resistance. However, these findings are exploratory and hypothesis-generating due to substantial missing data, a small number of resistant cases (n=24), and a single-center design. Prospective multicenter studies are needed to confirm these associations. Nonetheless, targeted interventions for HIV-positive patients and exposed contacts remain a priority.